logo
Patients will need extensive support after involuntary addiction treatment: Alberta agency

Patients will need extensive support after involuntary addiction treatment: Alberta agency

CBC24-03-2025

Social Sharing
An Alberta Crown corporation that studies addiction recommends that any involuntary treatment be done for longer time periods because shorter stays seem ineffective.
In a paper released on Friday, the Canadian Centre of Recovery Excellence (CoRE), an Alberta Crown corporation, says the province will need to provide a robust network of support after patients leave forced treatment centres if they want the approach to succeed.
"The goal is to say, 'Hey, look across the spectrum of things we can do. What's the best in class, and are there ways that we can offer this to the people who need it most?' " said Dr. Nathaniel Day, CoRE's scientific director and one of the paper's authors.
The United Conservative Party government in the 2023 provincial election pledged to introduce involuntary addiction treatment for adults.
The provincial government created CoRE last year to study the best ways to support addiction recovery.
CoRE spokesperson Katy Merrifield said the government asked CoRE to review existing evidence and similar models of involuntary treatment to advise the government on how to develop an Alberta program.
The government has said it will introduce what it calls "compassionate intervention" legislation this year, which would allow police, doctors, family members or a guardian to request mandatory drug treatment for a person with severe addiction.
Provincial data shows 1,182 people died of opioid poisoning in 2024 in Alberta. Although it was a 37 per cent drop from the previous year, an average of three people are dying each day.
Day and his co-authors reviewed research on involuntary treatment, which the paper calls "civil commitment," in Canada, the U.S., some European countries and Australia.
It says most of the research was done before the development of opioid agonist treatment, which consists of long-acting medications that can cut poisoning deaths by half.
The authors also looked at professionals such as nurses, pilots, doctors and dentists who were required to take drug treatment programs to retain their professional credentials or jobs. It's a group the report acknowledges is not a perfect comparison to the general population.
They found the "current literature is not adequate to determine the effect of civil commitment in general, or determine which interventions are beneficial and to what degree."
In the studies that tracked post-treatment deaths, five-to-10 per cent of people died.
The authors also found many patients who initially were forced into treatment were later compliant with recovery and grateful for the help.
They recommend keeping patients in treatment as long as the person needs, offering medications to prevent overdoses, help people find training or jobs, and offer follow-up therapy, peer support and check ins to help keep them sober.
The province should accept that some patients will have permanent brain damage and impairments and long-term mental illness and may need lifelong support, the says.
The report says patients should have access to appeals and review mechanisms for involuntary treatment, but doesn't recommend timelines.
Day said the province shouldn't be deterred by an absence of comprehensive studies.
"Just because something does not have clear literature, doesn't mean it isn't valuable," he said.
Psychiatrist worries about unaddressed harms
Dr. David Crockford, a University of Calgary psychiatrist who specializes in addiction medicine, and was not involved in the report, says the document fails to address some of the risks of involuntary therapy.
He said data from Australia shows a disproportionate number of Indigenous people and new immigrants in forced treatment.
Detaining and treating people who have already experienced trauma could lead to further feelings of distrust, and prevent some of those people from voluntarily seeking medical help in the future, he said.
There should also be short timelines in which patients can appeal their detention, like those included in the province's mental health legislation, he said.
"People can choose not to get the measles vaccine, can choose not to get the COVID vaccine and their rights are being vehemently upheld," he said. "And yet, people who are the most vulnerable are having their rights taken away from them, and being subject potentially to something which might be damaging."
Post-treatment overdose rates can also be higher in patients who were involuntarily treated compared to those who willingly participated, he said.
Crockford said it's unclear whether the recommendations apply to any substance addiction, including tobacco or cannabis, or just opioids. He said the authors don't define a "severe" addiction that could warrant involuntary treatment.
He said patients seeking voluntary treatment in Alberta still struggle getting access to detox and longer-term inpatient treatment centres. He said that system should be expanded before forcing people into treatment.
In a statement, Hunter Baril, press secretary to the minister of mental health and addictions, did not directly say how the government will use the CoRE recommendations.
"No jurisdiction in the world has built the system Alberta is building to bring people out of addiction and into recovery, including through treatment orders for those who have become a danger to themselves or others," the statement said.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

‘Pure joy, the giggles, the laughter': Kittens descend on B.C. ‘dementia village'
‘Pure joy, the giggles, the laughter': Kittens descend on B.C. ‘dementia village'

Global News

timea day ago

  • Global News

‘Pure joy, the giggles, the laughter': Kittens descend on B.C. ‘dementia village'

Joy, laughter, smiles and no shortage of meows. Those sounds echoed through the common area of Providence Living at The Views in Comox last Thursday as the facility was inundated with kittens, and they'll be back every week. The visit was the result of a new partnership between the Cats Society, a Vancouver Island rescue organization, and The Views, a facility that's already breaking ground as one of B.C.'s first 'dementia village' model long-term care homes. 2:20 A look inside B.C.'s new dementia long-term care model The idea for the initiative came to be after the son of one of The Views' residents, a board member of the CATS Society, brought his pet to visit and saw an opportunity to share the experience. Story continues below advertisement The result was the new program that brought a batch of baby felines to clamber, galavant, purr and snuggle with the facility's residents — and the results were magical. 'We see so much incredible connection, it is like sparks are flying everywhere, to be honest,' Kelly Romeril, The Views' director of operations, explained. Get weekly health news Receive the latest medical news and health information delivered to you every Sunday. Sign up for weekly health newsletter Sign Up By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy 'We see people reminiscing about the pets they had throughout their lives, we see people wanting to take them home and adopt them, we see staff members, family members and residents just in pure joy, the giggles, the laughter, you would just not believe it.' View image in full screen A resident of The Views cuddles with a kitten. Providence Living The Views is Canada's first publicly funded care home based on the dementia village, a European concept that eschews a hospital format and aims to create as much of a home-like environment as possible for residents. Story continues below advertisement Providence calls the model 'Home for Us,' and aims to expand it to all of its long-term care facilities in the long run. 'Part of moving … into a care home is a series of losses sometimes, so any time we can bring some of that joy back, we can bring those moments of connection and spontaneity and push away some of that loss and that boredom, it is a good thing to do and we welcome it,' Romeril said. 8:21 Inside Canada's first dementia village As a part of that mission, The Views has integrated the opportunity for animal contact in a variety of ways, welcoming chicks, baby ducks and goats from local hobby farms, along with therapy dogs from St. John Ambulance Canada, and various pets. Making regular visitors of kittens from the Cats Society is seen as a win-win, providing regular furry contact to residents and giving the young felines an opportunity for human socialization. Story continues below advertisement View image in full screen A kitten cuddles with a woman who lives at The Views in Comox. Providence Living 'Communication comes in so many ways, it's not always just about words, and there is something about connecting with another being, whether it is a human or an animal — when the connection happens, it is magical and words really aren't necessary,' Romeril said. 'And that's what we see a lot with pet visits, the words are not necessary, the love and the joy that's there and that's what matters.'

FILAMENT HEALTH ANNOUNCES AUTHORIZATION OF PHASE 2 CLINICAL TRIAL STUDYING BOTANICAL PSILOCYBIN FOR PROLONGED GRIEF DISORDER
FILAMENT HEALTH ANNOUNCES AUTHORIZATION OF PHASE 2 CLINICAL TRIAL STUDYING BOTANICAL PSILOCYBIN FOR PROLONGED GRIEF DISORDER

Cision Canada

time3 days ago

  • Cision Canada

FILAMENT HEALTH ANNOUNCES AUTHORIZATION OF PHASE 2 CLINICAL TRIAL STUDYING BOTANICAL PSILOCYBIN FOR PROLONGED GRIEF DISORDER

The clinical trial at Linkoping University will study Filament's botanical psilocybin drug candidate, PEX010 VANCOUVER, BC, June 11, 2025 /CNW/ - Filament Health Corp. (OTC: FLHLF) (" Filament" or the " Company"), a clinical‐stage natural psychedelic drug development company, today announced that the Swedish Ethical Review Authority and the Swedish Medical Products Agency have authorized a double-blind phase 2 clinical trial studying its botanical psilocybin drug candidate, PEX010, at Linkoping University. The trial will be the first to study the effects of psilocybin in the treatment of prolonged grief disorder. "In an aging society where people may outlive their family members by decades, it is crucial to develop treatment options for those with prolonged grief disorder," said Dr. Rebecca Böhme, Associate Professor at the Linkoping Center for Social and Affective Neuroscience. "This trial will assess whether psilocybin can improve adaptation to the loss experience. We are grateful to Filament Health for facilitating this research." People with prolonged grief disorder are at a 20 percent increased mortality risk. Previous psychological research suggests that the loss of a close person affects self-identity, an aspect of the higher cognitive self. Psilocybin is suggested to cause a transient shift from reliance on prior experiences towards current sensations. The clinical trial at Linkoping University will utilize this shift combined with a self-touch intervention to support re-learning about the bodily self in a trial population of 120 individuals. "We're pleased to provide PEX010 to Linkoping University for this much-needed area of research," said Benjamin Lightburn, Co-Founder and Chief Executive Officer at Filament Health. "This will be the ninth European clinical trial to study our drug candidate, positioning Filament as the region's leading supplier of GMP psilocybin." The trial at Linkoping University is expected to begin dosing in Q3 2025. PEX010 is authorized for investigation in 52 clinical trials worldwide for 14 mental health indications. ABOUT FILAMENT HEALTH (OTC:FLHLF) Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. Filament's platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines for clinical development. We are paving the way with the first-ever natural psychedelic drug candidates. Learn more at and on Twitter, Instagram, and LinkedIn. FORWARD LOOKING INFORMATION Certain statements and information contained in this press release and the documents referred to herein may constitute "forward‐looking statements" and "forward‐looking information," respectively, under Canadian securities legislation. Generally, forward‐looking information can be identified by the use of forward‐looking terminology such as, "expect", "anticipate", "continue", "estimate", "may", "will", "should", "believe", "intends", "forecast", "plans", "guidance" and similar expressions are intended to identify forward‐looking statements or information. The forward‐looking statements are not historical facts, but reflect the current expectations of management of Filament regarding future results or events and are based on information currently available to them. Certain material factors and assumptions were applied in providing these forward‐looking statements. Forward‐looking statements regarding the Company are based on the Company's estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of Filament to be materially different from those expressed or implied by such forward‐looking statements or forward‐looking information, including the timing and results of clinical trials, the ability of the parties to receive, in a timely manner and on satisfactory terms, the necessary regulatory, court and shareholders approvals; the ability of the parties to satisfy, in a timely manner, the other conditions to the completion of the proposed business combination; other expectations and assumptions concerning the transactions contemplated in the proposed business combination; the available funds of the parties and the anticipated use of such funds; the availability of financing opportunities; legal and regulatory risks inherent in the psychedelic drug development industry; risks associated with economic conditions, dependence on management and currency risk; risks relating to U.S. regulatory landscape; risks relating to anti-money laundering laws and regulation; other governmental and environmental regulation; public opinion and perception of the psychedelic drug development industry; risks related to the economy generally; risk of litigation; conflicts of interest; risks relating to certain remedies being limited and the difficulty of enforcement of judgments and effect service outside of Canada; and risks related to future acquisitions or dispositions. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward‐ looking statements and forward‐looking information. Filament will not update any forward‐looking statements or forward‐looking information that are incorporated by reference herein, except as required by applicable securities laws.

HIMSS Unites Global Healthcare Leaders to Shape the Future of Care: From Paris to Kuala Lumpur to Las Vegas
HIMSS Unites Global Healthcare Leaders to Shape the Future of Care: From Paris to Kuala Lumpur to Las Vegas

Cision Canada

time06-06-2025

  • Cision Canada

HIMSS Unites Global Healthcare Leaders to Shape the Future of Care: From Paris to Kuala Lumpur to Las Vegas

ROTTERDAM, Netherlands, June 6, 2025 /CNW/ -- Thousands of health and technology leaders will gather to share critical health technology insights to optimize care delivery and improve health outcomes at the 2025 HIMSS European Health Conference & Exhibition from 10-12 June in Paris. HIMSS (the Healthcare Information and Management Systems Society) is a non-profit organization that serves as a global health technology advisor and thought leader dedicated to improving health through information and technology. HIMSS supports health professionals and organizations through education, professional development, networking, and digital maturity assessment tools and advisory services that help transform the global health ecosystem. At HIMSS25 Europe, powerful speakers, hands-on sessions and data-powered case studies will spur dialogue around artificial intelligence, governance, cybersecurity, workforce development, and digital maturity. Following the European conference, all eyes turn to upcoming HIMSS conferences across the globe - the 2025 HIMSS APAC Health Conference & Exhibition in July in Kuala Lumpur; and the 2026 HIMSS Global Health Conference & Exhibition in March 2026 in Las Vegas. HIMSS conferences are part of a global strategy to support healthcare organizations and professionals through a professional society of more than 125,000 members and the HIMSS digital health maturity models – internationally recognized benchmarks to assess and advise health systems in critical areas such as analytics, infrastructure, community care and EMR management. HIMSS25 Europe: Advancing AI, Health Policy and Cybersecurity HIMSS25 Europe will be the epicenter for health professionals from more than 70 countries to explore critical themes: Artificial intelligence: World-class experts will demonstrate how to effectively and ethically utilize AI in healthcare. Regulatory leadership: European officials will dive into the EU AI Act, the Cyber Resilience Act and the European Health Data Space. Cybersecurity: Attendees will learn to respond to cyber threats, safeguard patient data and ensure rapid response to cyber risks. HIMSS25 APAC: Building Momentum HIMSS25 APAC will continue the global dialogue from 16-18 July in Kuala Lumpur. HIMSS partnered with Informa Markets to co-locate its APAC conference within International Healthcare Week 2025, Southeast Asia's premier healthcare event. HIMSS25 APAC will strengthen collaboration across health ministries, private sector leaders, clinicians and technology partners. Hundreds of expert speakers will lead discussions, share solutions, and spark ideas to help shape the future of healthcare. HIMSS26: Global Health Innovation Landing in Las Vegas Co-produced with Informa Markets, the 2026 HIMSS Global Health Conference & Exhibition will convene a diverse group of digital health experts from 9-12 March 2026 in Las Vegas. HIMSS26 will feature expanded AI and cybersecurity pavilions, plus workshops on nursing informatics, workforce development, interoperability, and much more. About HIMSS HIMSS (Healthcare Information and Management Systems Society) is a global advisor, thought leader and member-based society committed to reforming the global health ecosystem through the power of information and technology. As a mission-driven nonprofit, HIMSS offers a unique depth and breadth of expertise in digital health transformation, artificial intelligence, cybersecurity, workforce development, public policy, and research to advise leaders, stakeholders and influencers across the global health ecosystem on best practices. With a community-centric approach, our health innovation experts deliver key insights, education, advisory services, and engaging events to healthcare providers, payers, governments, and other health services organizations, ensuring they have the right information at the point of decision. HIMSS has served the global health community for more than 60 years, with focused operations across Americas, Europe, the United Kingdom, the Middle East and Asia-Pacific. Our members include more than 125,000 individuals and approximately 1,500 provider organizations, nonprofit partners and health services organizations. Our global headquarters is in Rotterdam, The Netherlands, and our Americas headquarters is in Chicago, Illinois. Join our global network at

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store